Clofibric-acid and GW-4064, as PPAR and FXR agonists, respectively, demonstrate significant anti-inflammatory and metabolic regulatory effects, indicating their potential in managing COPD-related inflammation. The gene discussed is NR1H4; the disease is chronic obstructive pulmonary disease.